Eli Lilly And Co (NYSE:LLY) Stock Holdings Lowered by Goelzer Investment Management Inc.

Goelzer Investment Management Inc. trimmed its position in Eli Lilly And Co (NYSE:LLY) by 0.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 311,501 shares of the company’s stock after selling 600 shares during the period. Eli Lilly And Co makes up 3.2% of Goelzer Investment Management Inc.’s holdings, making the stock its 2nd biggest holding. Goelzer Investment Management Inc.’s holdings in Eli Lilly And Co were worth $34,835,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Buckingham Capital Management Inc. grew its holdings in Eli Lilly And Co by 84.1% during the 1st quarter. Buckingham Capital Management Inc. now owns 3,713 shares of the company’s stock worth $482,000 after acquiring an additional 1,696 shares during the period. Private Trust Co. NA grew its holdings in Eli Lilly And Co by 3.8% during the 2nd quarter. Private Trust Co. NA now owns 6,314 shares of the company’s stock worth $699,000 after acquiring an additional 233 shares during the period. Pensionfund DSM Netherlands acquired a new stake in Eli Lilly And Co during the 2nd quarter worth $3,545,000. Pensionfund Sabic acquired a new stake in Eli Lilly And Co during the 2nd quarter worth $2,382,000. Finally, Verde Servicos Internacionais S.A. grew its holdings in Eli Lilly And Co by 36.8% during the 2nd quarter. Verde Servicos Internacionais S.A. now owns 49,756 shares of the company’s stock worth $5,512,000 after acquiring an additional 13,385 shares during the period. 77.37% of the stock is currently owned by institutional investors.

A number of analysts have commented on the stock. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. UBS Group lowered their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Finally, Bank of America started coverage on shares of Eli Lilly And Co in a report on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price for the company. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Eli Lilly And Co has an average rating of “Buy” and an average price target of $130.03.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $116.37, for a total value of $24,437,700.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the completion of the sale, the senior vice president now directly owns 38,306 shares in the company, valued at $4,325,130.46. The disclosure for this sale can be found here. Over the last three months, insiders have bought 8,405 shares of company stock worth $909,004 and have sold 614,473 shares worth $70,558,302. Company insiders own 0.11% of the company’s stock.

Shares of NYSE LLY traded down $0.38 during midday trading on Wednesday, reaching $112.79. 229,137 shares of the stock were exchanged, compared to its average volume of 7,631,578. The business has a 50-day simple moving average of $110.45 and a two-hundred day simple moving average of $112.63. The company has a market capitalization of $109.00 billion, a price-to-earnings ratio of 20.32, a P/E/G ratio of 1.86 and a beta of 0.16. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $132.13. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. The company had revenue of $5.48 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the firm posted $1.39 earnings per share. Equities research analysts expect that Eli Lilly And Co will post 5.78 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $0.645 per share. The ex-dividend date is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.29%. Eli Lilly And Co’s dividend payout ratio is 46.49%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Exchange-Traded Funds (ETFs)

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.